Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063574 | 1.00 | AKR1C3 (0.43) | AKR1C3AKR1C2ABCG2MAPK14TEAD1 | |
| SCHEMBL25791053 | 0.91 | TP53 (0.46) | AKR1C3AKR1C2ABCG2MAPK14NPC1 | |
| SCHEMBL21090803 | 0.89 | AKR1C3 (0.41) | AKR1C3AKR1C2ABCG2TEAD1YAP1 | |
| SCHEMBL30061302 | 0.89 | AKR1C3 (0.41) | AKR1C3AKR1C2ABCG2TEAD1YAP1 | |
| SCHEMBL21090794 | 0.89 | AKR1C3 (0.46) | AKR1C3AKR1C2RAB9ATP53SMN1; SMN2 | |
| SCHEMBL29438919 | 0.89 | AKR1C3 (0.46) | AKR1C3AKR1C2RAB9ATP53SMN1; SMN2 | |
| SCHEMBL21054627 | 0.89 | AKR1C3 (0.51) | AKR1C3AKR1C2ABCG2TEAD1YAP1 | |
| SCHEMBL30062663 | 0.89 | AKR1C3 (0.51) | AKR1C3AKR1C2ABCG2TEAD1YAP1 | |
| SCHEMBL30062661 | 0.88 | AKR1C3 (0.45) | AKR1C3AKR1C2ABCG2TEAD1YAP1 | |
| SCHEMBL21054808 | 0.88 | AKR1C3 (0.45) | AKR1C3AKR1C2ABCG2TEAD1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | YAP1, TEAD2, TEAD3 | AKR1C3 4086/4885AKR1C2 3536/4885ABCG2 2776/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | AKR1C3 2063/4885AKR1C2 1874/4885ABCG2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.